BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Heart disease risk greater for women with a common condition they may not be aware they have - 223 Most Amusing Messages At any point Sent Among Kids and Their Folks
- 36 Monetary Arranging Administrations for Your Necessities
- 44 astronauts are en route home from ISS after medical issue forces early exit
- 5What to know as New York City nurses strike for a 3rd day
- Best bar-b-que Style: Which One Is Your Number one?
- Vote In favor of Your Favored Kind Of Organic product
- Is an $85 apple pie worth it? Our Thanksgiving taste test says … maybe.
- Where America’s CO2 emissions come from – what you need to know, in charts
- Trump signs a law returning whole milk to school lunches
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- ‘More should be done’: UN pushes Syrian regime on justice for Druze, Alawites and minority groups
- Massachusetts court hears arguments in lawsuit alleging Meta designed apps to be addictive to kids
- What you need to know about Trump accounts as Michael and Susan Dell donate $6 billion to the new early childhood investment program
